Impact of the COVID-19 pandemic on the healthcare and lives of myeloma or AL amyloidosis patients and their caregiversAL amyloidosis, MPE, Myeloma, Patient evidenceJune 21, 2021
MPE interviews experts about different aspects of the CARAMBA clinical trialMyeloma, VideosApril 10, 2023
FDA grants talquetamab (TALVEY™) accelerated approval for relapsed or refractory myelomaAccess, MyelomaAugust 14, 2023
FDA approves elranatamab (ELREXFIO™) for relapsed or refractory myelomaAccess, MyelomaAugust 21, 2023
EMA recommends expansion of melphalan flufenamide (Pepaxti®) marketing authorisationAccess, MyelomaSeptember 18, 2023
EMA CHMP recommends non-renewal of marketing authorisation for Blenrep®Access, MyelomaSeptember 22, 2023
European Commission approves talquetamab for the treatment of relapsed and refractory myelomaAccess, MyelomaAugust 22, 2023
